An observational study in Adult Diffuse Astrocytoma, Adult Mixed Glioma and Adult Oligodendroglioma, sponsored by Radiation Therapy Oncology Group. Completed at 41 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-18.
Sponsored by Radiation Therapy Oncology Group · Observational
This trial studies the natural history of brain function, quality of life, and seizure control in patients with brain tumor who have undergone surgery. Learning about brain function, quality of life, and seizure control in patients with brain tumor who have undergone surgery may help doctors learn more about the disease and find better methods of treatment and on-going care.
PRIMARY OBJECTIVES:
I. To determine if there is difference in the average changes of neurocognitive function (NCF) scores from baseline to the time of radiologic tumor progression or up to 5 years (whichever occurs first), between radiologically progressed and non-progressed patients.
SECONDARY OBJECTIVES:
I. To determine if there is difference in the time to neurocognitive decline, as defined by the Reliable Change Index - Within subjects Standard Deviation (RCI-WSD), between radiologically progressed and non-progressed patients.
II. To evaluate NCF during the postoperative observational period of progression-free survival (PFS) and after radiological progression for a total time on study of 5 years.
III. To determine if the changes in cognitive functioning are an early warning biomarker for radiological progression.
IV. To explore the effect of salvage therapy on cognitive outcomes in patients who progress during the study period for up to 5 years.
V. To evaluate quality-of-life (QOL) as measured by the European Organization for Research and Treatment of Cancer (EORTC) QOL-30 and QOL brain module (BCN20) and health utilities as measured by the European Quality of Life-5 Dimensions (EQ-5D), for a total time on study of 5 years.
VI. To evaluate seizure control for a total time on study of 5 years. VII. To evaluate molecular correlates of QOL, NCF, seizure control, and PFS. VIII. To characterize aberrant molecular pathways in low-grade gliomas (LGGs) and test the hypothesis that activation of signaling pathways will predict worse PFS and overall survival (OS).
IX. To explore the relationship between change in cognitive function and symptomatic progression (defined as worsening seizures or new or progressive neurologic deficits) or clinical progression (defined as initiation of treatment interventions such as radiotherapy, chemotherapy, or additional surgery).
OUTLINE:
Patients undergo neurocognitive assessment using the CogState Test battery (the Detection Test (DET), the Identification Test (IDN), the One Card Learning Test (OCLT), and the Groton Maze Learning Test (GMLT)) at baseline* and at 12, 24, 36, 42, 48, 54, and 60 months. Patients also complete the EORTC Quality of Life Questionnaire-Core 30 (QOL-30), the Brain Cancer Module-20 (BCM20), and the European Quality of Life-5 Dimensions (EQ-5D) questionnaires at baseline*, at 12, 24, 36, 48, and 60 months afterwards, and before undergoing any further treatment. Patients are instructed to complete a seizure and medication diary during study.
Patients undergo MRI scans at baseline*, at 12, 24, 36, 48, and 60 months, and at the time of radiological, clinical, or neurological failure.
NOTE: * 12 weeks after surgery.
1,397 studies on the registry are indexed under Glioma; 351 are open to participants now.
This study's enrollment of 82 is close to the median of 88 across 238 observational studies indexed under Glioma.
Browse Glioma studies →Radiation Therapy Oncology Group is the lead sponsor of 154 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Central pathology-confirmed diagnosis of supratentorial grade II oligodendroglioma, astrocytome or mixed oligoastrocytoma prior to Step 2 registration.
The patient must be within one of the following categories:
Maximal safe resection with minimal residual disease defined as follows:
OR Age \<40 (any extent of resection) OR Age \<50, preoperative tumor diameter \<4 cm (any extent of resection)
Inclusion Criteria:
No multifocal disease, based upon the following minimum diagnostic work-up:
The patient must be within one of the following categories:
Maximal safe resection with minimal residual disease defined as follows:
If there is > 2 cm post-operative residual T2/FLAIR abnormality and the neurosurgeon believes this represents edema and not primarily tumor, the neurosurgeon is encouraged to repeat imaging within the allowed study period (up to 84 days post-operatively) to confirm resolution of edema
Patients undergo neurocognitive assessment using the CogState Test battery (the DET, the IDN, the OCLT, and the GMLT) at baseline\* and at 12, 24, 36, 42, 48, 54, and 60 months. Patients also complete the EORTC QOL-30, the BCM20, and the EQ-5D questionnaires at baseline\*, at 12, 24, 36, 48, and 60 months afterwards, and before undergoing any further treatment. Patients are instructed to complete a seizure and medication diary during study. Patients undergo MRI scans at baseline\*, at 12, 24, 36, 48, and 60 months, and at the time of radiological, clinical, or neurological failure.
Procedure: cognitive assessment · Procedure: magnetic resonance imaging · Other: laboratory biomarker analysis · Other: questionnaire administration · Procedure: quality-of-life assessment
Undergo neurocognitive assessment
Undergo MRI
Also known as: MRI, NMR imaging, NMRI, nuclear magnetic resonance imaging
Correlative studies
Ancillary studies
Ancillary studies
Also known as: quality of life assessment
NCF as measured by each of the 4 neurocognitive tests (DET, IDN, OCLT, GMLT)
Each of the battery's tests will be evaluated using the 2-sample t-test with a 2-sided significance level of 0.05 to determine if there is a clinically meaningful difference in the average change of NCF score from baseline to the time of radiologic tumor progression or up to 5 years (whichever occurs first) between radiologically progressed and non-progressed patients. In order to adjust for multiple comparisons and maintain the overall type I error of 0.05, Hochberg's procedure will be applied.
Time frame: Up to 5 years
Time to neurocognitive decline in patients who progress and who do not progress radiologically, as defined by the RCI-WSD
The cumulative incidence approach will be used to estimate the median time to neurocognitive impairment to account for the competing risk of death and to determine if there is a clinically meaningful difference in the time to neurocognitive decline, as defined by the RCI-WSD (reliable change index-within-subjects standard deviation), between radiologically progressed and non-progressed patients.
Time frame: Up to 5 years
PFS
Estimated using the Kaplan-Meier method, and difference between the activation of different signaling pathways will be tested using the log rank test. Multivariate analyses with the Cox proportional hazards model for PFS will be performed to assess the activation of the signaling pathway effect adjusting for patient-specific risk factors. The covariates to be evaluated for the multivariate models are: activation of signaling pathway status, age, tumor size, and other prognostic factors.
Time frame: The interval from registration to progression or death, whichever occurs first, assessed up to 5 years
Radiological progression
To determine if the NCF decline is an earlier warning biomarker to radiologic progression, we will use NCF change as a time-dependent covariate in a Cox proportional hazards (PH) regression model with radiological progression as the endpoint. The Cox model estimates the ratio of hazard rate of radiographic failure with and without neurocognitive decline. Anticonvulsant use, tumor size, tumor histology, and further treatment received if recurrence is discovered, which may also have impact on the radiological progression, will also be considered in this Cox PH regression analysis.
Time frame: Up to 5 years
Effect of salvage therapy on cognitive outcomes in patients who progress
Time frame: Up to 5 years
QOL as measured by the EORTC QOL-30, EORTC QOL-BCN20, and EQ-5D
The general linear mixed-effects model will be used to evaluate the changes of QOL and health utilities over time.
Time frame: Up to 5 years
Frequency of seizures, evaluated using patient seizure diary
Marginal models will be used to evaluate the change of frequencies of seizures over time for up to 5 years. Anticonvulsant use, tumor size, tumor histology, further treatment received if recurrence is discovered, and other prognostic factors will also be included in the covariates sets. The available molecular marker information will also be included as a covariate to evaluate the molecular correlates of seizure frequency.
Time frame: Up to 5 years
Molecular correlates of QOL, NCF, seizure control, and PFS
Time frame: Up to 5 years
OS
Estimated using the Kaplan-Meier method, and difference between the activation of different signaling pathways will be tested using the log rank test. Multivariate analyses with the Cox proportional hazards model for OS will be performed to assess the activation of the signaling pathway effect adjusting for patient-specific risk factors. The covariates to be evaluated for the multivariate models are: activation of signaling pathway status, age, tumor size, and other prognostic factors.
Time frame: Up to 5 years
Symptomatic or clinical progression
Symptomatic and clinical progression will be explored for the correlation with cognitive changes in addition to radiological progression.
Time frame: Up to 5 years
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Radiation Therapy Oncology Group